05 February 2021>: Articles
Intermittent High-Frequency Percussive Ventilation Therapy in 3 Patients with Severe COVID-19 Pneumonia
Unusual clinical course, Challenging differential diagnosis, Unusual or unexpected effect of treatment
Sergey P. Marchenko B* , Ecaterina Scarlatescu A , Paul Robert Vogt A , Alexey Naumov A , Sergey Bognenko ADOI: 10.12659/AJCR.928421
Am J Case Rep 2021; 22:e928421
Table 1. Comorbidities, treatment, and laboratory findings.
Patient case number and DOD | Comorbidities | Treatment | Laboratory findings | |||||
---|---|---|---|---|---|---|---|---|
WBC (109/l); (L/N ratio) | CRP (mg/l) | LDH (U/l) | D-dimers (µg/l) | Ferritin (µg/l) | ||||
1 | DOD 16 | Obesity, AH | LMWH, HCQ, AZT | 8.5; (1.2) | 66 | 300 | 500 | 319 |
DOD 21 | LMWH, HCQ, AZT | 5.9; (1.3) | 206 | 216 | 1099 | 502 | ||
DOD 27 | LMWH, HCQ, AZT | 13.2;(1.2) | 15 | 209 | 580 | 296 | ||
2 | DOD 11 | Obesity, AH, HF, AF, DM | LMWH, HCQ, AZT, spironolactone, torsemide, metoprolol, enalapril | 6.1; (1.3) | 76.4 | 233 | 1180 | 195 |
DOD 18 | LMWH, HCQ, AZT, DXM, metoprolol, spironolactone, enalapril | 1.4;(1.6) | 90.2 | 330 | 515 | 240 | ||
DOD 25 | LMWH, HCQ, meropenem, DXM, torsemide, spironolactone, enalapril | 12.8; (1.3) | 184.3 | 693 | 757 | 1092 | ||
DOD 31 | LMWH, metoprolol, torsemide, spironolactone, enalapril | 6.0;(1.8) | 34.7 | 402 | 681 | 371 | ||
3 | DOD 12 | Obesity, AH | LMWH, HCQ, AZT | 5.3; (1.8) | 61.3 | 226 | 190 | 433 |
DOD 16 | LMWH, HCQ, AZT | 2.9; (1.9) | 85.7 | 283 | 334 | 306 | ||
DOD 18 | LMWH, meropenem, DXM | 15.2; (1.9) | 94.3 | 199 | 402 | 320 | ||
DOD 23 | LMWH | 4.2; (2.8) | 2.5 | 181 | 311 | 180 | ||
WBC – white blood cell; N – neutrophils; L – lymphocytes; CRP – C-reactive protein; LDH – lactate dehydrogenase, DOD – day of disease onset; HCQ – hydroxychloroquine; AZT – azithromycin; LMWH – low molecular weight heparin; AH – arterial hypertension; HF – heart failure; DM – diabetes mellitus; AF – atrial fibrillation; DXM – dextromethorphan. |